Pages that link to "Q73611440"

The following pages link to The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis (Q73611440):

Displaying 31 items.

• Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma (Q25255751) (← links)
• Raynaud's phenomenon: new aspects of pathogenesis and the role of nailfold videocapillaroscopy (Q28084234) (← links)
• Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management (Q28392431) (← links)
• Oxidative damage and antioxidative therapy in systemic sclerosis (Q28394733) (← links)
• Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis (Q33947213) (← links)
• Treatment of Raynaud's phenomenon: new insights and developments (Q35082016) (← links)
• Autoimmune disorders: a concept of treatment based on mechanisms of disease (Q35600096) (← links)
• Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. (Q35954604) (← links)
• Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. (Q36396428) (← links)
• Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers (Q36434142) (← links)
• New lines in therapy of Raynaud's phenomenon (Q37335947) (← links)
• Vascular disease in scleroderma (Q37344793) (← links)
• Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis (Q37690287) (← links)
• New insights into the mechanism of notch signalling in fibrosis. (Q38026842) (← links)
• Animal models of scleroderma: current state and recent development (Q38154834) (← links)
• Fibrogenesis, novel lessons from animal models (Q38542592) (← links)
• Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis (Q38603115) (← links)
• Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants (Q38909892) (← links)
• Oxidative Stress and Skin Fibrosis (Q42984072) (← links)
• Primary and secondary Raynaud's phenomenon (Q46626152) (← links)
• Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis (Q46894547) (← links)
• Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis (Q50700264) (← links)
• A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis (Q57072741) (← links)
• The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy (Q58705720) (← links)
• Raynaud’s phenomenon (Q61646575) (← links)
• Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis (Q64114719) (← links)
• Current Treatment Options in Raynaud's Phenomenon (Q73245541) (← links)
• Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis (Q79263337) (← links)
• Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis (Q81510541) (← links)
• Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis (Q83825039) (← links)
• Antioxidant Effect of Epigallocatechin-3-Gallate in a Bleomycin-Induced Scleroderma Model (Q94418545) (← links)